It may be possible to treat BCR-ABL CML and FLT3-ITD AML more effectively by blocking the SIRT1 network along with TKIs or FLT3 inhibitors [183]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.